Hypertonic Saline (NaCl 7.5 %) Reduces LPS-Induced Acute Lung Injury in Rats

Carregando...
Imagem de Miniatura
Citações na Scopus
24
Tipo de produção
article
Data de publicação
2015
Editora
SPRINGER/PLENUM PUBLISHERS
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
INFLAMMATION, v.38, n.6, p.2026-2035, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Acute respiratory distress syndrome (ARDS) is the most severe lung inflammatory manifestation and has no effective therapy nowadays. Sepsis is one of the main illnesses among ARDS causes. The use of fluid resuscitation is an important treatment for sepsis, but positive fluid balance may induce pulmonary injury. As an alternative, fluid resuscitation with hypertonic saline ((HS) NaCl 7.5 %) has been described as a promising therapeutical agent in sepsis-induced ARDS by the diminished amount of fluid necessary. Thus, we evaluated the effect of hypertonic saline in the treatment of LPS-induced ARDS. We found that hypertonic saline (NaCl 7.5 %) treatment in rat model of LPS-induced ARDS avoided pulmonary function worsening and inhibited type I collagen deposition. In addition, hypertonic saline prevented pulmonary injury by decreasing metalloproteinase 9 (MMP-9) activity in tissue. Focal adhesion kinase (FAK) activation was reduced in HS group as well as neutrophil infiltration, NOS2 expression and NO content. Our study shows that fluid resuscitation with hypertonic saline decreases the progression of LPS-induced ARDS due to inhibition of pulmonary remodeling that is observed when regular saline is used.
Palavras-chave
fluid resuscitation, focal adhesion kinase, nitric oxide, acute lung injury, pulmonary fibrosis
Referências
  1. Khan R, 2011, SHOCK, V36, P440, DOI 10.1097/SHK.0b013e3182336bda
  2. Yamasawa H, 1999, INFLAMMATION, V23, P263
  3. Angle N, 1998, SHOCK, V9, P164, DOI 10.1097/00024382-199803000-00002
  4. Steinberg J, 2003, J SURG RES, V111, P185, DOI 10.1016/S0022-4804(03)00089-1
  5. Davey A, 2011, EUR RESPIR J, V38, P959, DOI 10.1183/09031936.00032111
  6. Oliveira RP, 2002, CRIT CARE, V6, P418
  7. Marshall R, 1998, THORAX, V53, P815
  8. Faffe DS, 2000, EUR RESPIR J, V15, P85, DOI 10.1183/09031936.00.15108500
  9. HANTOS Z, 1992, J APPL PHYSIOL, V72, P168
  10. Cely CM, 2010, CRIT CARE MED, V38, P1126, DOI 10.1097/CCM.0b013e3181d56fae
  11. Petroni RC, 2012, SHOCK, V37, P524, DOI 10.1097/SHK.0b013e31824c7665
  12. VELASCO IT, 1980, AM J PHYSIOL, V239, pH664
  13. Parra ER, 2006, J HISTOCHEM CYTOCHEM, V54, P1315, DOI 10.1369/jhc.6A6969.2006
  14. Yu GF, 2012, PULM PHARMACOL THER, V25, P27, DOI 10.1016/j.pupt.2011.10.003
  15. Zeisel MB, 2005, J IMMUNOL, V174, P7393
  16. Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
  17. UHLIG S, 1995, AM J PATHOL, V146, P1235
  18. Hagiwara S, 2007, LUNG, V185, P31, DOI 10.1007/s00408-006-0085-1
  19. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  20. Sime PJ, 2001, CLIN IMMUNOL, V99, P308, DOI 10.1006/clim.2001.5008
  21. Vincent JL, 2011, MINERVA ANESTESIOL, V77, P1190
  22. Staudenmayer KL, 2005, SHOCK, V23, P459, DOI 10.1097/01.shk.0000160523.37106.33
  23. Hsu YC, 2007, FREE RADICAL BIO MED, V42, P599, DOI 10.1016/j.freeradbiomed.2006.11.031
  24. Kabir K, 2002, SHOCK, V17, P300, DOI 10.1097/00024382-200204000-00010
  25. Lagares D, 2012, ARTHRITIS RHEUM-US, V64, P1653, DOI 10.1002/art.33482
  26. Gueders MM, 2006, EUR J PHARMACOL, V533, P133, DOI 10.1016/j.ejphar.2005.12.082
  27. Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
  28. Bihari S., 2013, SHOCK
  29. Del Sorbo L, 2010, CURRENT OPINION CRIT, V17, P1
  30. Mu E., 2011, THROMB RES, V129, P479
  31. Theobaldo MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074369
  32. van Haren FM, 2011, SHOCK, V37, P268
  33. Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564
  34. Yuan S.Y., 2011, MICROVASC RES, V83, P82